Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilbert Lefèvre

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Journal of Clinical Pharmacology|March 29, 2007
Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site applicationGilbert Lefèvre, Greg Sedek, Hsun-Lun Aaron Huang, et al.
Malaria Journal|September 10, 2013
Evaluation of two novel tablet formulations of artemether-lumefantrine (Coartem) for bioequivalence in a randomized, open-label, two-period studyGilbert Lefèvre, Prafulla Bhad, Jay Prakash Jain, et al.
Clinical and Translational Science|June 26, 2020
A Pooled Analysis of Three Randomized Phase I/IIa Clinical Trials Confirms Absence of a Clinically Relevant Effect on the QTc Interval by UmibecestatStefan Viktor Vormfelde, Nicole Pezous, Gilbert Lefèvre, et al.
Journal of Clinical Pharmacology|October 5, 2002
Interaction trial between artemether-lumefantrine (Riamet) and quinine in healthy subjectsGilbert Lefèvre, Polly Carpenter, Claire Souppart, et al.
Antimicrobial Agents and Chemotherapy|June 15, 2011
Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malariaAbdoulaye A Djimdé, Mamadou Tekete, Salim Abdulla, et al.
Journal of Clinical Pharmacology|February 28, 2009
Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patchGilbert Lefèvre, Monika Büche, Greg Sedek, et al.
Antimicrobial Agents and Chemotherapy|August 13, 2014
A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteersF Joel Leong, Ruobing Li, Jay Prakash Jain, et al.
The American Journal of Tropical Medicine and Hygiene|January 11, 2012
Randomized, prospective, three-arm study to confirm the auditory safety and efficacy of artemether-lumefantrine in Colombian patients with uncomplicated Plasmodium falciparum malariaGabriel Carrasquilla, Clemencia Barón, Edwin M Monsell, et al.
AIDS (London, England)|May 24, 2013
Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatmentMohammed Lamorde, Pauline Byakika-Kibwika, Jonathan Mayito, et al.
Malaria Journal|September 7, 2010
Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjectsSalim Abdulla, Baraka Amuri, Abdunoor M Kabanywanyi, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Journal of Clinical Pharmacology|March 29, 2007
Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site applicationGilbert Lefèvre, Greg Sedek, Hsun-Lun Aaron Huang, et al.
Malaria Journal|September 10, 2013
Evaluation of two novel tablet formulations of artemether-lumefantrine (Coartem) for bioequivalence in a randomized, open-label, two-period studyGilbert Lefèvre, Prafulla Bhad, Jay Prakash Jain, et al.
Clinical and Translational Science|June 26, 2020
A Pooled Analysis of Three Randomized Phase I/IIa Clinical Trials Confirms Absence of a Clinically Relevant Effect on the QTc Interval by UmibecestatStefan Viktor Vormfelde, Nicole Pezous, Gilbert Lefèvre, et al.
Journal of Clinical Pharmacology|October 5, 2002
Interaction trial between artemether-lumefantrine (Riamet) and quinine in healthy subjectsGilbert Lefèvre, Polly Carpenter, Claire Souppart, et al.
Antimicrobial Agents and Chemotherapy|June 15, 2011
Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malariaAbdoulaye A Djimdé, Mamadou Tekete, Salim Abdulla, et al.
Journal of Clinical Pharmacology|February 28, 2009
Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patchGilbert Lefèvre, Monika Büche, Greg Sedek, et al.
Antimicrobial Agents and Chemotherapy|August 13, 2014
A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteersF Joel Leong, Ruobing Li, Jay Prakash Jain, et al.
The American Journal of Tropical Medicine and Hygiene|January 11, 2012
Randomized, prospective, three-arm study to confirm the auditory safety and efficacy of artemether-lumefantrine in Colombian patients with uncomplicated Plasmodium falciparum malariaGabriel Carrasquilla, Clemencia Barón, Edwin M Monsell, et al.
AIDS (London, England)|May 24, 2013
Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatmentMohammed Lamorde, Pauline Byakika-Kibwika, Jonathan Mayito, et al.
Malaria Journal|September 7, 2010
Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjectsSalim Abdulla, Baraka Amuri, Abdunoor M Kabanywanyi, et al.
Pageof 3